HR(+)/HER2(−) de novo metastatic breast cancer: a true peculiar entity?

De novo metastatic breast cancer (dnMBC) accounts for ~6–10% of all breast cancers and for ~30% of MBC with increasing incidence over time. Hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR(+)/HER2(−)) tumours are the most frequent subtype with a similar incidence to th...

Descripción completa

Detalles Bibliográficos
Autores principales: Torrisi, Rosalba, Jacobs, Flavia, Miggiano, Chiara, De Sanctis, Rita, Santoro, Armando
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioExcel Publishing Ltd 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012832/
https://www.ncbi.nlm.nih.gov/pubmed/36926051
http://dx.doi.org/10.7573/dic.2022-12-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10012832/
https://www.ncbi.nlm.nih.gov/pubmed/36926051
http://dx.doi.org/10.7573/dic.2022-12-2

Ejemplares similares